Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable ...

However, Eli Lilly isn't done. With Jacob Van Naarden, the Eli Lilly executive put in charge of identifying acquisition ...

Eli Lilly is far from a one-trick pony.

By Padmanabhan Ananthan June 3 (Reuters) - Ascidian Therapeutics said on Wednesday it has signed a licensing deal for its ...

Macro strategist Jordi Visser delivered a striking observation on a recent episode of The Pomp Podcast with Anthony Pompliano ...

CNBC’s Angelica Peebles sits down with Lilly’s President of Oncology and Head of Business Development at the largest global ...

SpaceX looks like a rocket, but don't fly too close to the sun. Here's why Eli Lilly is likely a better stock to own.

The primary engine behind the huge revenue expansion is its Mounjaro, powered by the active ingredient tirzepatide. The drug, sold as Mounjaro for type 2 diabetes and Zepbound for obesity, helped grow ...

CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered ...

Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat inherited kidney diseases, through ...

By Sriparna Roy May 28 (Reuters) - CVS Health will restore Eli Lilly's weight-loss injection Zepbound to its list of covered ...